Latest News
Read All NewsEvent
Speakers
Melinda Irwin, Ph.D., M.P.H.
Associate Dean of Research
Susan Dwight Bliss Professor of Epidemiology (Chronic Diseases)
Yale School of Public Health
Dr. Melinda L. Irwin is the Susan Dwight Bliss Professor of Epidemiology and Associate Dean of… read more
Consider attending these AACR sessions virtually or in-person to learn the latest from DCP.
Saturday, April 26, 2025
ED20 - Early Detection of Primary Cancer and Minimal Residual Disease by Liquid Biopsies
EDUCATIONAL SESSION 8:00 AM - 9:30 AM CT… read more
Speaker
Xiaoshuang Feng, Ph.D.
Scientist
Cancer Epidemiology Branch
International Agency for Research on Cancer (IARC)
World Health Organization (WHO)
Biography
I am an early-career scientist working in the Risk Assessment and Early Detection (RED) team… read more
Speaker
Kelly Rentscher, Ph.D.
Assistant Professor
Department of Psychiatry and Behavioral Medicine
MCW Cancer Center Scholar
Medical College of Wisconsin
Dr. Rentscher obtained her Ph.D. in Clinical Psychology from the University of Arizona and completed… read more
Speaker
Rina S. Fox, Ph.D., M.P.H.
Assistant Professor
University of Arizona College of Nursing
Tucson, AZ
Biography
Dr. Rina S. Fox is an Assistant Professor at the University of Arizona College of Nursing, as well as a member of the Cancer Prevention… read more
Speaker
Atieh Hajirahimkhan, Ph.D.
NCI NRSA Postdoctoral Fellow
Department of Surgery
Lurie Cancer Center Translational Bridge Fellow
Robert H. Lurie Comprehensive Cancer Center
Feinberg School of Medicine
Northwestern University
Dr. Atieh… read more
Studying the evolution of cancer malignancy in space and time provides clues that are crucial for understanding how tumors develop, how they evade the immune system, and how they resist therapy and recur. Since 2018, the Human Tumor Atlas Network (HTAN), a US National Cancer Institute (NCI)-funded… read more
Survivorship in Patients with Multiple Myeloma Treated with Chimeric Antigen Receptor T-Cell Therapy
Speaker
Laura Oswald, Ph.D.
Department of Health Outcomes and Behavior
Moffitt Cancer Center
Dr. Laura Oswald is a tenure-track Assistant Member in the Department of Health Outcomes and Behavior at Moffitt Cancer Center in Tampa, FL. She earned a PhD in… read more
Speaker
Alexandra Harris, Ph.D., M.P.H.
Cancer Prevention Fellow, NCI, NIH
Biography
Dr. Alexandra R. Harris is a postdoctoral fellow and transdisciplinary breast cancer researcher at the National Cancer Institute (NCI), with joint appointments in the… read more
Speaker
Shih-Ting "Christine" Wang, Ph.D.
Assistant Professor, Department of Material Science and Engineering, Northwestern University
Biography
Dr. Christine Wang is a biomaterials engineer specializing in bioactive materials for medical applications. As… read more
The Tomosynthesis Mammographic Imaging Screening Trial (TMIST) has reached its enrollment goal of 108,508 women, as announced today by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN). The study, funded by the National Cancer Institute (NCI), one of the National Institutes of Health, will now… read more
Over the last five decades, the number of deaths from many cancer types has dropped substantially in the U.S. A range of factors have played a role in this decrease. These include better treatments, prevention efforts such as smoking cessation, and nationwide screening campaigns to catch cancers—or… read more
Read the full newsletter here:
https://www.cp-ctnet-dmacc.org/public/updates/newsletters/newsletter-20…
This webinar is rescheduled from January 28, 2025.
Join us to kick off the 2025 season of Building Bridges in Cancer Symptom Science, where we will focus on the complex issue of cancer cachexia. Drs. Erin Talbert and Eric Roeland will share their perspectives on developing… read more
At the present time, all NIH-sponsored meetings are cancelled. We apologize for any inconvenience this may cause and appreciate your understanding. This webinar is postponed and will be rescheduled at a later date.
Speaker
Mary Luz Rol, Ph.D.
Scientist… read more
Speaker
Matthew Schabath, Ph.D.
Moffitt Distinguished Scholar
Senior Member
Moffitt Cancer Center
Tampa, FL
Matthew Schabath, Ph.D. is a Moffitt Distinguished Scholar and Senior Member at the Moffitt Cancer Center with joint appointments in the Departments… read more
The National Cancer Institute (NCI) has selected two assays to be included in the Vanguard Study on multi-cancer detection (MCD) tests which will be conducted by the Cancer Screening Research Network (CSRN). The two assays selected, in alphabetical order, are the Avantect® Multi-Cancer Detection… read more
The Cancer Prevention Fellowship Program (CPFP), NCI’s distinctive postdoctoral fellowship program that combines independent, mentored research with training in translational cancer prevention science, population health, leadership, and communication, is nearing its 40th anniversary. In light of… read more
Improvements in cancer prevention and screening have averted more deaths from five cancer types combined over the past 45 years than treatment advances, according to a modeling study led by researchers at the National Institutes of Health (NIH). The study, published Dec. 5, 2024, in JAMA… read more
Questions and Answers about MCD Tests
Learn how MCD tests work, risks involved with these tests, and potential benefits.
More than half of cancer deaths involve cancers that have no recommended screening tests, including highly deadly cancers like ovarian and pancreatic cancer.1 Multi-cancer… read more
The National Cancer Institute (NCI) Division of Cancer Prevention (DCP) is pleased to announce the 2025 cohort of the DCP Early Career Scientist Spotlight Research Seminar Series. These nine investigators are advancing research within prevention, detection,… read more
For those participating in the 2024 Symposium, consider attending these sessions to learn about the latest from DCP-funded research from NCORP and the Grand Challenges Program.
Check out the full online program: https://sabcs.org/FullProgram
Wednesday December 11, 12:30 PM CT
Poster Session 1… read more
Integrative medicine service for cancer is an approach to medical care that recognizes the benefit of combining conventional (standard) therapies (such as chemotherapy, radiation, and surgery) with complementary therapies (such as acupuncture, herbal… read more
Integrative medicine service for cancer is an approach to medical care that recognizes the benefit of combining conventional (standard) therapies (such as chemotherapy, radiation, and surgery) with complementary therapies (such as acupuncture, herbal… read more
Presentations from the DCP-funded NCI ULACNet and CASCADE Programs at the 2024 International Papillomavirus Conference
The 36th International Papillomavirus Conference & Basic, Clinical and Public Health Scientific Workshops (IPVC 2024) will be held in Edinburgh, UK, November 12-15, 2024. The… read more
In July, the Food and Drug Administration (FDA) approved the first blood test to use as primary screening for people at average risk for colon cancer. Although some experts said they are excited about the prospect of the Shield test to screen for colorectal cancer, they also cautioned that it’s… read more
The use of telehealth in cancer care surged during the COVID-19 pandemic, when, for a period of time, in-person medical care was limited and many visits to the doctor went virtual. Despite some recent pullbacks in telehealth flexibilities, many experts believe that telehealth will continue to have… read more
The 2024 BMES Annual Meeting will take place on October 23-26, 2024 in Baltimore, MD.
Learn more about the BMES Annual Meeting.
Breast cancer is the second most common cancer in women behind skin cancer, with approximately 13.1% of women estimated to receive a diagnosis of breast cancer at some point in their lifetime. The National Cancer Institute (NCI) is pioneering research to understand how we can better prevent breast… read more
This hybrid NASEM MCD workshop will examine the state of the science for clinical use of multi-cancer detection (MCD) tests. The NCI Division of Cancer Prevention staff will present on Monday, October 28. Videos of the speaker presentations and speaker slides are available in the “About” section of… read more
The Biomedical Engineering Society (BMES) Annual Meeting will be held October 23-26, 2024, in Baltimore. “Synergizing Research and Cultural Excellence” is this year’s theme.
The NCI Division of Cancer Prevention staff will be presenting on October 24th.… read more
Speaker
Sarah Blagden, M.D., Ph.D.
Department of Oncology
Medical Sciences Division
University of Oxford
Sarah Blagden is a clinician-scientist (M.D., Ph.D.) at the University of Oxford with a more than 20-year established track record of clinical and… read more
This webinar focused on the role of cancer caregivers in promoting symptom management and optimal cancer outcomes. The speakers discussed the importance of addressing caregivers’ well-being during cancer and interventions designed for the patient-caregiver dyad to optimize health and quality of… read more
Researchers have found that olanzapine may be more effective in controlling severe nausea and improving the quality of life in patients with cancer who are undergoing treatment with chemotherapy, according to new findings presented at the 2024 ASCO Quality Care Symposium (Abstract 185). The study… read more
The NCI Community Oncology Research Program (NCORP) selected Judith Hopkins, M.D., and Kristina Gardner, M.H.A. as recipients of this year’s outstanding principal investigator (PI) and administrator, respectively, at the 2024 NCORP annual meeting in Bethesda, Maryland. NCI’s Marge Good, RN, M.P.H… read more
At the Rare Cancers Prevention and Interception workshop this year, cancer researchers from across the United States, Canada, and the United Kingdom and from across disciplines sought to address many of the issues that can hamper research progress for these diseases.
Despite the name, rare cancers… read more
Lynch syndrome, also known as hereditary non-polyposis colorectal cancer (HNPCC), is the most common inherited genetic change that increases the risk of several kinds of cancer including colorectal cancer. About 3% of all colorectal cancers in the United States occur in people with these inherited… read more
Program Solicitation PHS 2025-1
Program Solicitation PHS 2025-1 is now available [View solicitation].
Proposals due: Friday, October 18, 2024, at 5:00 p.m. ET
PHS 2025-1 NCI SBIR Contract Solicitation Webinar: Thursday, August 22, 2024, from 2:00 p.m. to 3:30 p.m. ET
The National… read more
This webinar will focus on HPV-related head and neck cancer (HNC). The incidence of HNC, including oropharyngeal cancer (OPC), is on the rise in many countries, with a significant number of OPC cases caused by human papillomavirus (HPV) infections. Current… read more
This pre-application webinar will be held for prospective applicants to provide an overview of the NOFO for the CP-CTNet Sites.
CP-CTNet Sites (RFA-CA-24-024)
Date: Tuesday, August 27
Time: 1:00-2:00 p.m. ET
Register in advance
Questions after the webinars can be sent to CP-CTNet@mail.… read more
This pre-application webinars will be held for prospective applicants to provide an overview of the NOFO for the CP-CTNet DMASC.
CP-CTNet: DMASC (RFA-CA-24-025)
Date: Tuesday, August 27
Time: 2:30-3:30 p.m. ET
Register in advance
Questions after the webinars can be sent to CP-CTNet@mail.nih… read more
Speaker
Fan Zhang, Ph.D.
Assistant Professor
Department of Pharmaceutics
University of Florida
Fan Zhang, Ph.D. received his Ph.D. from Johns Hopkins University in Materials Science & Engineering. His graduate work established the guiding principles… read more
Speaker
Neeha Zaidi, M.D.
Assistant Professor of Oncology
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Neeha Zaidi is a physician-scientist and oncologist who focuses on the development of vaccine strategies for the treatment and… read more
Speaker
Fahriye Duzagac, Ph.D.
Division of Cancer Prevention & Population Sciences Cancer Prevention Research Training Program (CPRTP) Postdoctoral Fellow
Department of Clinical Cancer Prevention
MD Anderson Cancer Center
Date of presentation: … read more
On May 14, the Food and Drug Administration (FDA) expanded the approvals of two tests that detect cancer-causing types of human papillomavirus (HPV) in the cervix. Both tests are used as part of screening for cervical cancer.
In this NCI Cancer Currents Blog DCP's Dr. Vikrant Sahasrabuddhe… read more
Interventions for Cancer-related Cognitive Impairment (CRCI)
Date: Monday, August 26, 2024
Time: 3:00 - 4:00 p.m. ET
In this installment of the Building Bridges in Cancer Symptom Science Webinar Series, the speakers focused on interventions for cancer-related cognitive impairment. Dr. Agnès… read more
In this webinar, Dr. Hinds reviewed advances in the screening and evaluation of fatigue in children and adolescents/young adults during and following cancer treatment. Dr. Kadan-Lottick then addressed the factors that contributed to fatigue, summarized evidence-based approaches to its treatment,… read more
In this kick-off webinar, Dr. Patricia A. Ganz provided a keynote address on the state of symptom science research. The field of cancer symptom science comprised researchers and clinicians from both preclinical and clinical settings who were dedicated to the identification, mechanistic… read more
Speaker
Florencia McAllister, M.D.
Associate Professor,
Department of Clinical Cancer Prevention, and
Department of Gastrointestinal (GI) Medical Oncology,
Division of Cancer Medicine,
The University of Texas MD Anderson Cancer Center,
Houston,… read more
View the June 2024 issue
Overview and goals of the workshop:
To enhance our understanding of diet-host-microbiome interrelationships and their impact on mucosal immunity and health outcomes, the Office of Nutrition Research (ONR) and NIAID, in collaboration with many other… read more
Speaker
Venkateshwar Madka, Ph.D.
Assistant Professor
Department of Medicine
Preclinical Bioassay Director
Center for Cancer Prevention and Drug Development
Stephenson Cancer Center
University of Oklahoma Health Sciences Center
Date of presentation: … read more
Purpose
Oral microbiology is evolving from studying the individual bacteria to the relationship between oral microecological balance and systemic diseases. It is necessary to identify gaps in knowledge regarding interactions among oral bacteria, viruses,… read more
Consider attending these ASCO sessions to learn about the latest from the DCP symptom science and screening research programs, DCP-funded research from NCORP, and to hear from NCI Director W. Kimryn Rathmell, M.D., Ph.D.
Check out the full online program with session and on demand/on device links… read more
NCI’s Cancer MoonshotSM Tolerability Consortium is developing new ways to analyze clinical- and patient-reported data to better understand tolerability of cancer treatment and the patient experience.
For decades, cancer patients have participated in clinical trials of new therapies, and clinicians… read more
Gastric (stomach) cancer is a leading cause of death in the United States (US). The cancer burden, however, is differentially distributed across racial/ethnic groups, with non-White individuals exhibiting the highest incidence and mortality rates. Because of the lack of epidemiologic and clinical… read more
Researchers funded by NCI have developed and validated a new prostate cancer urinary biomarker test that can help differentiate who should proceed for biopsy after an elevated prostate-specific antigen (PSA) test from those who can wait.
The 18-gene test, called MyProstateScore version 2.0, or… read more
The main goals of the meeting are to:
Foster the exchange of ideas and potentially new collaborative interactions among leading cancer prevention researchers from basic and clinical research,
Highlight new and emerging trends in immunoprevention and… read more
Speaker
Chemtai Mungo, M.D., M.P.H.
Assistant Professor
Obstetrics and Gynecology
University of North Carolina
Chapel Hill
Date of presentation: Wednesday, May 29, 2024 | 12pm EST
Dr. Chemtai Mungo is an Assistant Professor of Obstetrics and… read more
Speaker
Drew Weissman, M.D., Ph.D.
Roberts Family Professor in Vaccine Research
Professor of Medicine
Director of Vaccine Research in the Infectious Disease Division
Director of the Penn Institute for RNA Innovation
Perelman School of Medicine
University of… read more
We want to create a multidisciplinary cancer prevention research community and spark new collaborations to enable advances in future cancer prevention approaches. Attendees will hear insights across the research continuum, from discovery biology through to… read more
In this webinar, Dr. Alberti discussed methods for studying chemotherapy-induced peripheral neuropathy (CIPN) in preclinical studies and building collaborative translational teams. Dr. Smith then addressed methods and techniques for assessing CIPN in clinical trials.
Speakers
Paola Alberti, M.D… read more
Speaker
Jennifer Young, Ph.D.
Assistant Professor
Department of Medical Social Science
Feinberg School of Medicine
Northwestern University
Evanston, IL
Dr. Jennifer Young is a trained Marriage and Family Therapist and a researcher specializing… read more
Speaker
Jonathan Villena-Vargas, M.D.
Assistant Professor of Clinical Cardiothoracic Surgery
Weill Cornell Medicine
Date of presentation: Friday, April 19, 2024 | 11am EST
As a Thoracic Surgeon and Early-Stage Investigator at Weill Cornell Medicine,… read more
The Immuno-Oncology Translational Network (IOTN) Capstone meeting will highlight scientific accomplishments across the IOTN. This will be a hybrid meeting held May 14-15, 2024 with both virtual and in person (Masur Auditorium, Building 10, NIH Bethesda main campus… read more
Speaker
Thomas N. Robinson, M.D., M.P.H.
Irving Schulman, MD Endowed Professor in Child Health
Professor of Pediatrics, of Medicine
Epidemiology and Population Health
Stanford University.
designs solutions to help children and families improve their… read more
NCI researchers have published a review in CA: A Cancer Journal for Clinicans that outlines what is known and unknown about multi-cancer detection assay technologies. “MCD tests can potentially be used to improve early cancer detection, including cancers that currently lack effective… read more
The main goals of the workshop are to:
Identify challenges and knowledge gaps and explore research opportunities in rare cancers research.
Identify research gaps and develop strategic planning with emphasis on understudied research areas in rare cancers.
Explore important research questions… read more
As improved cancer treatments have led to increased cancer survivorship, cancer survivors are now living longer with chronic pain. NCI is supporting research (search key word: pain) to address this issue.
Pain is one of the most common symptoms experienced… read more
The NCI’s Cancer Prevention Fellowship Program (CPFP) is excited to announce that CPFP Acting Branch Director, Dr. Jessica Faupel-Badger, is presenting, “Chemoprevention: An Evolving Definition,” at the ASPO 48th Annual Meeting, on Monday, March 18, 2024, from 10:30 to 11:15 AM (CDT) during… read more
Latest News, Upcoming Events, In Case you Missed It, Reminders
Consider attending these DCP PREVENT-funded project presentations at AACR to learn about preclinical development of innovative interventions and biomarkers for cancer prevention and interception.
See also
DCP Participation at American Association for Cancer Research (AACR) Annual Meeting, April 5-… read more
Consider attending these AACR sessions to learn about the latest DCP funding opportunities in cancer prevention, interception, and symptom science; research resources and workforce activities; multi-cancer detection tests and risk screening; future research needs; and more.
See also
DCP/PREVENT-… read more
PHILADELPHIA – The American Association for Cancer Research (AACR) will present the 2024 AACR Distinguished Public Service Award for Lifetime Achievement in Cancer Research to Franco Cavalli, MD, and the 2024 AACR Distinguished Public Service Award posthumously to Worta McCaskill-Stevens… read more
The National Institutes of Health (NIH) has launched a clinical trials network to evaluate emerging technologies for cancer screening. The Cancer Screening Research Network (CSRN) will support the Biden-Harris administration’s Cancer Moonshot℠ by investigating how to identify cancers… read more
Date: Tuesday, February 27, 2024
Time: 3:30pm ET
The Cancer Prevention Fellowship Program (CPFP) is a renowned postdoctoral training program providing a strong foundation in the field of cancer prevention research to a multidisciplinary cadre of… read more
Speaker
Rick Kittles, Ph.D.
Senior Vice President for Research
Morehouse School of Medicine
Atlanta, GA
Dr. Kittles was previously Professor and founding Director of the Division of Health Equities within the Department of Population Sciences at the… read more
See the full newsletter here: https://www.cp-ctnet-dmacc.org/public/updates/newsletters/newsletter-20…
Speaker
Peter S. Hovmand, Ph.D., M.S.W.
Pamela B. Davis M.D. Ph.D. Professor of Medicine
Interim-director and Professor
Center for Community Health Integration
School of Medicine and Professor in Biomedical Engineering
Case School of Engineering
Case… read more
‘Last Mile’ Initiative Will Test Alternative Approach to Screening Through the SHIP Trial Network
The ‘Last Mile’ Initiative SHIP Trial Network was announced today at the White House Cervical Cancer Forum by NCI Director Dr. Kimryn Rathmell.
On January 25, 2024, the National Cancer Institute (NCI… read more
Findings from two studies aimed at learning more about preventing the type of esophageal cancer with the fastest growing incidence rate have emerged recently from the Barrett’s Esophagus Translational Research Network (BETRNet) as it winds down its collaborative activities… read more
Many common cancers occur either exclusively or more often in men than women. Our current understanding of why this is true is inadequate. The purpose of the webinar series, The Role of Androgens in Cancers in Men is to highlight what is currently known, gaps in our understanding, and opportunities… read more
Many common cancers occur either exclusively or more often in men than women. Our current understanding of why this is true is inadequate. The purpose of the webinar series, The Role of Androgens in Cancers in Men is to highlight what is currently known, gaps in our understanding, and opportunities… read more
Carlos Alvarado Quesada (born in San José, 1980) was the forty-eighth President of the Republic of Costa Rica (2018-2022). Under his leadership, Costa Rica contributed to global efforts to combat climate change, defended human rights, democracy, and… read more
There are multiple approved medications to reduce the risk of breast cancer. However, the chances of those medications causing toxic side effects can lead many people to forego preventive interventions. Two recent studies supported by the NCI Division of… read more
The National Cancer Institute (NCI) Division of Cancer Prevention (DCP) is pleased to announce the inaugural cohort of the DCP Early Career Scientist Spotlight Research Seminar Series. The new series of public seminars will highlight nominated early career… read more
Worta McCaskill-Stevens, M.D., a medical oncologist, former director of the NCI Community Oncology Research Program (NCORP), and a tireless champion of addressing cancer disparities, passed away peacefully on November 15, 2023. We share our deep condolences… read more
Dietary habits have increasingly been recognized as modifiable risk factors in the development of colorectal cancer, with particular attention given to the role of polyunsaturated fatty acids (PUFA). During this webinar, you will learn about the potential of PUFA as a preventive agent against… read more
Please join the NCI Division of Cancer Prevention Immunology Interest Group (DCP IIG) seminar series talk focused on cancer prevention, interception, and immuno-oncology.
Speaker
Elizabeth M. Jaffee, M.D., FAACR, FACP, FAAAS
The Dana and Albert “Cubby”… read more
Speaker
Susan Magasi, Ph.D., M.S.
Professor and Head of the Department of Occupational Therapy
University of Illinois Chicago
University of Illinois Cancer Center
Dr. Magasi is passionate about issues of health and participation equity for people with… read more
Nationwide Effort Begins to Find Permanent Leader
Brandy Heckman-Stoddard, Ph.D., M.P.H., Chief of the National Cancer Institute (NCI) Division of Cancer Prevention (DCP) Breast and Gynecologic Cancer Research Group (BGCRG) has been named Acting Chief of… read more
A healthier diet has been associated with reduced risk of a number of diseases, including cancer, but the mechanisms of how that actually works continue to be investigated, including in laboratory and animal studies. The following studies carried out by DCP grantees are looking to understand the… read more
On September 28 - 29, 2023, the National Heart, Lung, and Blood Institute (NHLBI), National Cancer Institute (NCI), National Institute on Aging (NIA), National Institute of Neurological Disorders and Stroke (NINDS), and the Office of Dietary Supplements (ODS) convened a 2-day virtual workshop open… read more
Two recent publications focus on widely used treatments for other diseases to evaluate possible roles in the prevention of cancer. One looked at the potential of statins, a common heart disease drug, to prevent gynecologic cancers, and the other examined whether metformin, a drug for type 2… read more
On May 1-2, 2023, approximately 70 experts from academia, government, industry, and professional organizations globally met with the goal of developing a contemporary working definition or framework for the term ‘precancer.’ While there have been a number of working definitions proposed… read more
National Cancer Institute (NCI) Director Monica Bertagnolli, M.D., today announced the creation of the NCI Worta McCaskill-Stevens Career Development Award for Community Oncology and Prevention Research (K12). This training award, focused on community oncology and cancer prevention, is named… read more
David S. Alberts, M.D., a former director of the University of Arizona Cancer Center, died in late July. As a scientist who was an early and unending advocate for cancer prevention medicine, he will always have the deep gratitude of the National Cancer Institute Division of Cancer Prevention (DCP… read more
Cardio-oncology research looks at cancer treatment-related cardiotoxicity, or damage to the heart and cardiovascular system (including heart valves and vessels) that can occur during or after cancer treatment. Over the last decade, efforts from the National Cancer Institute (NCI) in this area, as… read more
New self-sampling technologies screening for HPV could help increase access and reduce cervical cancer among underserved and high-burden populations.
The National Cancer Institute’s Last Mile initiative is exploring new ways at getting screening tests for cervical cancer into more hands. Women who… read more
Speaker
Robert H. Vonderheide, M.D., D.Phil.
Director of the Abramson Cancer Center,
Vice Dean of Cancer Programs, PSOM,
Vice President for Cancer Programs, UPHS
University of Pennsylvania
Robert H. Vonderheide, M.D., D.Phil., is Director of the Abramson… read more
After receiving an initial single dose of the HPV vaccine Gardasil 9, children aged 9 to 11 had high levels of two key antibodies that protect against HPV infections and cancer for up to 2 years before receiving their delayed booster dose, according to results from a clinical trial supported by the… read more
Speaker
John C. Mathers, Ph.D.
Human Nutrition & Exercise Research Centre
Centre for Healthier Lives
Population Health Sciences Institute
Newcastle University
United Kingdom
Dr. Mathers is a principal investigator for a portfolio of research projects in the areas of nutrition and the… read more
This is an open workshop and free to attend. Registration is required.
Results from two NCI-supported studies relating to symptom management were among the significant findings presented at the June 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO). The study results, which both incorporated data from… read more
Scientists consider the role of overweight and obesity in increasing the risk for gastrointestinal cancers to be well established, with colorectal cancers the most common of these malignancies in the United States. According to National Cancer Institute (NCI) data, an estimated 153,020 men and… read more
Multi-cancer detection tests could be the key to finding certain cancers earlier, screening for multiple cancers at one time and boosting overall survival rates.
The National Cancer Institute has established a third Cancer Screening Research Network that will leverage emerging technologies and… read more
Obesity is associated with and likely plays a causal role in at least thirteen types of cancer. Worsening obesity tends to increase serum concentrations of glucose, insulin, insulin-like growth factor-1 (IGF-1), lipids, leptin, estrogen, resistin, and inflammatory cytokines and reduces IGF-binding… read more
More than a century after Aldred Scott Warthin, M.D., Ph.D., a pathologist at the University of Michigan, first suspected heredity lay behind one family’s numerous cancers, scientists have begun testing two experimental vaccines they hope will prevent or delay cancers associated with the inherited… read more
This meeting will bring together grantees funded through the Provocative Questions mechanism that addressed intermittent fasting and time-restricted eating (TRE). Presentations and group discussions will focus on lessons learned and key gaps in TRE research.
Speakers
Time-restricted eating:… read more
Speaker
Damon Centola, Ph.D.
Elihu Katz Professor of Communication, Sociology and Engineering
University of Pennsylvania
Director of the Network Dynamics Group
Senior Fellow
Leonard Davis Institute of Health Economics
Dr. Centola is one of the world's… read more
The NCI Division of Cancer Prevention Immunology Interest Group (DCP IIG) is pleased to announce the launch of a new seminar series focused on cancer prevention, interception, and immuno-oncology. Please join us for the upcoming inaugural seminar.
Speaker… read more
We are posting this article in May for Hepatitis Awareness Month.
Despite intense research, liver cancer prevention remains a challenge, experts say, with efforts directed at underlying conditions that can significantly raise an individual’s risk.… read more
April 14-19, 2023
DCP/PREVENT-Funded Poster Presentations
Poster Session: Late Breaking Poster
April 17, 2023, 9:00 a.m. - 12:30 p.m.
LB114 - Colon cancer preventive efficacy of ONC201 and naproxen alone or in combination in FAP relevant PIRC rat model
Venkateshwar Madka, Gopal Pathuri,… read more
This pre-application webinar for the Cancer Immunoprevention Network is co-sponsored by the NCI Division of Cancer Biology and the NCI DIvision of Cancer Prevention. Speakers will be: Lillian Kuo, Ph.D., program official in the Division of Cancer Biology and Altaf Mohammed, Ph.D., program official… read more
Speaker
Yamile Molina, Ph.D., M.P.H., M.S.
Associate Professor
Division of Community Health Sciences
School of Public Health
Associate Director for Community Engaged Research
Mile Square Health Center
Associate Director for Community Outreach &… read more
Speaker
Yelena Wu
Associate Professor
Department of Dermatology
Investigator
Huntsman Cancer Institute
University of Utah
Dr. Wu is a pediatric and clinical child psychologist. She completed her bachelor’s degree in psychology at the… read more
The Discovery and Development of Natural Products for Cancer Interception and Prevention Program (DDNP-CIP) supports the discovery and development of new natural products that are safe, non-toxic, and efficacious for cancer interception and prevention. The Program Official for this RFA and the main… read more
To invite developers of Multi-Cancer Detection (MCD) Assays to partner with NCI and have their assays considered for the new Vanguard Study
Speaker
Natalia Rodriguez, Ph.D., M.P.H.
Assistant Professor
Public Health and Biomedical Engineering
Purdue University
Associate Director of Population Health and Health Equity
Regenstrief Center for Healthcare Engineering
Dr. Rodriguez earned… read more
When Chadwick Boseman, the charismatic star of “Black Panther,” died at age 43 from stage 4 colorectal cancer in 2020, it put a celebrity face on a disease once thought to occur primarily later in life. The actor’s untimely death highlighted a troubling national trend: the rising number of… read more
Speaker
Andrea Cheville, M.D., M.S.
Professor of Physical Medicine and Rehabilitation
Medical Director
Patient-Centered Outcomes Program
Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery
Mayo Clinic
Rochester, MN.
Dr. Cheville… read more
The executive summary of the second PARTNRS (Primary Care Alliance in Research Trials Involving NCORP Sites) Workshop is now available.
PARTNRS is a strategic initiative to encourage and forge partnerships between oncologists and primary care providers to promote patient accrual into cancer… read more
Speaker
James DeGregori, Ph.D.
Courtenay C. and Lucy Patten Davis Endowed Chair in Lung Cancer Research
Dept. of Biochemistry and Molecular Genetics
University of Colorado Anschutz Medical Campus
School of Medicine
Aurora, CO
James DeGregori is a Professor… read more
The 5th Virtual Joint Meeting of the NCI Board of Scientific Advisors and the National Cancer Advisory Board. This is the 3rd and final day of the Joint Board Meeting.
This is the 6th Virtual Joint Meeting of the National Cancer Advisory Board and the NCI Board of Scientific Advisors, scheduled for 3 days, 13-15 June 2022. 3rd Day - 15 June, Full Virtual Board Meeting, from 1:00 p.m. to 5:00 p.m.
Speaker
Jennifer Tsui, Ph.D.
Associate Professor
Population and Public Health Sciences
Keck School of Medicine
University of Southern California
Dr. Tsui is a health services researcher and cancer prevention and control scientist with a focus on… read more
Researchers have recruited the first vaccine candidates to one of two new prevention trials that seek to immunize high-risk individuals against cancers associated with Lynch syndrome, the most common cause of hereditary colorectal cancer. Individuals who inherit the condition have an estimated… read more
Vaccines against the hepatitis B virus can prevent chronic hepatitis B infection that can lead to liver cirrhosis and liver cancer.
Human papillomavirus (HPV) vaccines can prevent infection with viruses that can cause cervical cancer and many other cancers.
Cancer prevention interventions available today include:
Medications proven to reduce risk of breast and colon cancers in those at increased risk.
Lowering risk by avoiding or controlling things known to cause cancer, like tobacco use.
Treatments for infections known to increase… read more
can be from the tumor and/OR the treatment
can continue after successful cancer treatment ends
an be acute (short-term) or chronic (long-lasting)
Controlling pain is an important part of your cancer treatment plan.
NCI supports research to understand and treat all types of pain.
For more… read more
Almost every cancer patient reports some fatigue
Length and depth of sleep may not relieve fatigue
Cancer patients can experience mental fatigue as well as physical fatigue
NCI-supported studies of exercise, including yoga, have shown that activity reduces symptoms of fatigue for some cancer… read more
Most often studied in women with breast cancer but seen in many types of cancer, cognitive deficits may be caused by the cancer or its treatment, including surgery and chemotherapy. Common problems affect:
learning and retaining information
trouble concentrating and difficulties in… read more
Cancer patients don't usually have just one symptom related to cancer treatment, often they have several that cluster together.
Examples of symptom clusters include:
fatigue, pain, sleep disturbances, cognitive difficulties, depression
nausea, vomiting, anorexia, fatigue
NCI supports… read more
Liquid biopsy is useful when:
not enough tissue sample is available
not enough tumor tissue is in a sample
a tumor is hard to reach
regular monitoring is needed
Liquid biopsies are analyzed for:
presence of cancer cells
DNA
other substances released by tumors
PREVENT Cancer Preclinical Drug Development Program (PREVENT) supports the best ideas in cancer prevention using NCI contract resources
The 134 projects in PREVENT involve:
79 Chemoprevention
46 Immunoprevention
9 Biomarkers
Preclinical Drug Development Pipelines involves… read more
The NCI Community Oncology Research Program (NCORP) brings cancer research studies and results to patients in a variety of community settings across the United States
7 Research Bases Develop and coordinate clinical trials and cancer care research for 32 Community Sites and 14 Minority/Underserved… read more
For the inaugural post of the Cancer Prevention Science blog, the focus is on the ongoing critical study of 2-D vs. 3-D mammography for breast cancer screening known as TMIST. Next time, Deborah Winn, Ph.D., acting director of the Division of Cancer Prevention, will answer questions about this… read more
Cancer Prevention Science editors spoke with Deborah Winn, Ph.D., acting director of the NCI Division of Cancer Prevention, about cancer prevention and early detection research in the division and beyond.
Why is cancer prevention research important?
One important way to make sustained progress… read more
Pancreatic Cancer – New Onset Diabetes
About 1 in 100 people with new onset diabetes are diagnosed with pancreatic cancer within 3 years of their diabetes diagnosis; 1 in 4 people diagnosed with pancreatic cancer were first diagnosed with diabetes.
See a… read more
As cancer researchers delve into the many molecular processes that guide cell life within the body, NCI is looking for ways to characterize and measure different substances in this process, with an eye to identifying who has cancer or who is at risk for the disease. One ongoing funding opportunity… read more
77% - Localized: About a third of the men in this category are eligible to choose Active Surveillance
13% - Regional
6% - Distant
4% - Unknown
Dr. Howard Parnes
In the path toward understanding the development and ultimate prevention of prostate cancer, researchers are studying how to keep low-grade, early stage prostate cancer being monitored on Active Surveillance from progressing to… read more
Members of the US-Latin American-Caribbean Clinical Trials Network and National Cancer Institute researchers work together to improve and optimize approaches for prevention of HPV-related cancers in people living with HIV.
Cervical cancer is highly… read more
While researchers have identified some of the genetic changes that lead to cancer development, a key knowledge gap remains: finding the genetic changes that drive the development of cancers that arise at an earlier age than average (early onset) in racially and ethnically diverse populations.… read more
EsoCheck™ and EsoGuard™
NCI Annual Plan & Budget Proposal for Fiscal Year 2020 (PDF, 17.4 MB)
A new technology coupled with a new biomarker test now in clinical trials are giving patients timely access to a quick, accurate and less invasive way to… read more
Pancreatic Cancer - New Onset Diabetes
About 1 in 100 people with new onset diabetes are diagnosed with pancreatic cancer within 3 years of their diabetes diagnosis
1 in 4 people diagnosed with pancreatic cancer were first diagnosed with diabetes
Last Reviewed: June 20, 2023
As the availability and sophistication of smart technology for health (such as wearables, sensors, and micro-robotic tools) continues to increase, these devices could prove transformative in cancer prevention. Two ongoing Division of Cancer Prevention (DCP) funding opportunities are promoting the… read more
Research to uncover how and why benign gynecologic conditions like endometriosis or uterine fibroids progress to invasive and deadly ovarian cancer or uterine sarcomas, is a critical and overlooked issue in women’s health. A new report on research priorities and an open funding opportunity are… read more
DCP Director Philip E. Castle, Ph.D., M.P.H.
In the month of October, breast cancer awareness is the health message that looms large. Yet, researchers across the National Cancer Institute and across the world are focused on breast cancer all the time. In… read more
If you were concerned that you might be at increased risk for a specific kind of cancer, what would you do to confirm that risk, and what would you be willing to do to reduce that risk? The answer is likely to be, "it depends on your doctor."
Quotes from Focus Group Participants
"The claim of… read more
The SWOG Cancer Research Network is opening to accrual the MiCHOICE Trial to study the use of decision support tools by women with high-risk breast conditions and their healthcare providers to choose among chemoprevention options. The MiCHOICE Trial was previously mentioned in the November 19… read more
DCP Director Philip E. Castle, Ph.D., M.P.H.
As this unforgettable year of 2020 comes to an end, I am reaching the milestone of my first 6 months as Director of the NCI Division of Cancer Prevention (DCP). It has been a whirlwind of virtual meetings and… read more
An over-the-counter drug, readily available to consumers for years, may open a new option for preventing colorectal cancer in high-risk individuals.
It's not the mouse that roared but the quiet mouse behind the scenes that inspired researchers to look at the anti-inflammatory drug, naproxen, said… read more
Millions of older Americans take aspirin daily to reduce their risk for heart disease and colorectal cancer. But, new data suggests this protective edge for colorectal cancer comes only if they begin taking aspirin before age 70.
In a pooled analysis of two… read more
During chemotherapy for an advanced blood cancer, Stacey Blansky vaped marijuana daily for her nausea and used cannabis oil for anxiety and stress. The decision to add these complex, plant-derived substances to ease her treatment’s side effects came after doing her own research on possible… read more
For centuries, visionary physicians have stressed preventing disease as the best option. I frequently say that the “best” cancer is the cancer that never happens. Today, we turn our attentions to the scientists who made stride after stride during the last 50 years to shape cancer prevention… read more
After decades of opposition to decriminalizing cannabis products (especially marijuana), a more permissive attitude toward cannabis and its derivative products has taken hold today at the state level. At the same time, inconsistencies in state policies conflict with federal law, which itself,… read more
Pancreatic Cysts Are Monitored in New Trial Aimed at Reducing Cancer Risk Through Targeted Screening
In a new NCI-sponsored study now recruiting participants, investigators will evaluate two different screening strategies for non-cancerous pancreatic cysts to determine which works best at detecting early malignancy.
Even though few of these sac-like structures are likely to develop into… read more
NCI and CDC experts will discuss the importance of cancer prevention and screening for many cancers, the progress that has been made in the past 50 years in these fields, and share the successes of cervical cancer screening and prevention, including a focus on the human papillomavirus (HPV) vaccine.
On May 3, Sudhir Srivastava presented on Early Detection Research Network (EDRN).
On Demand
Session Type: Major Symposium
Session Title: Colorectal Cancer Interception: Immunologic and Pharmacologic Advances
Companion session to Live Panel discussion Thursday, April 15 at 1:30 PM
Multiantigen vaccines for Colon Cancer Prevention, Shizuko Sei, National Cancer… read more
Scientists have identified more than 1,000 potential new biomarkers for cancer that they hope will aid in the early detection of many of these complex diseases, including one of the most challenging, pancreatic cancer.
Pancreatic cancers have long defied… read more
Preventing cancer today and in the future lies at the heart of the National Cancer Institute’s competitive postdoctoral fellowship program, which is accepting candidate applications for the 2022 class until August 16, 2021.
Fellowship Program Application
The CPFP application period is now CLOSED… read more
Bob Aronson was only 54 years old and, in the words of his son Tom, “extremely healthy.”
“So it was really surprising to everyone when he went in for an annual routine eye exam and his eye doctor suspected diabetes,” Tom recalled.
With his diabetes diagnosis confirmed, Bob got back to his normal… read more
One of the first-ever vaccines for the prevention of colorectal and other cancers in patients at high genetic risk for these malignancies is expected to start its early phase safety and immunogenicity trial in the first quarter of 2022, according to investigators… read more
Philip Castle, Ph.D., M.P.H., joined NCI in July 2020 as director of the Division of Cancer Prevention (DCP). Dr. Castle previously worked at NCI in the Division of Cancer Epidemiology and Genetics (2002–2010), where he led numerous research projects, including studies of HPV and its connection to… read more
In 2020, a year of unimaginable tragedy, an estimated 375,000 people died from Covid-19 infections in the United States alone. Much of the suffering and death due to the disease was preventable in three ways: through avoidance by wearing masks and social distancing; by screening and treatment; and… read more
Being a teenager or young adult is hard enough. Add a cancer diagnosis, and the challenges—which can range from severe fatigue to financial stress—are likely to multiply.
Researchers in gynecologic oncology have begun testing a promising surgery for premenopausal women at high genetic risk for ovarian cancer that avoids early menopause and may prevent these malignancies from developing.
Studies have shown that most ovarian cancers actually begin to grow from cancer… read more
Agenda
Download the Agenda (PDF, 41.96 KB)
Speakers
Nadir Arbor
Jane Armitage
John Baron
John Burn
Andrew Chan
Jack Cuzick
Raymond DuBois
Ernie Hawk
Ruth Langley
Peter Rothwell
Asad Umar
This Healthcast podcast commemorates the National Cancer Act's 50th anniversary by highlighting the progress the National Cancer Institute has made in cancer prevention. Leaders in NCI's Division of Cancer Prevention talk about avoidance, screening and treatments, and vaccinations, and how… read more
A year ago, I said that coming on board as the Division of Cancer Prevention Director in July 2020 was a “challenge,” adding that I had faith in science that the pandemic would be solved soon. Science has brought us a vaccine against SARS-CoV-2 and… read more
In a clinical study underway, scientists hope to unravel the complexities of a group of poorly understood and relatively rare blood disorders that often lead to cancer. In myelodysplastic syndromes (MDS), the problem arises when normal blood cells fail to function properly or are ill-formed inside… read more
The first day of autumn was September 22nd. Fall reminds us that change can be a beautiful process. It’s the season that conjures up memories of heading back to school, visits to the pumpkin patch, jumping in piles of colorful leaves, picking apples at the orchard, drinking apple cider, and making… read more
The National Cancer Institute’s Pancreatic Cancer Detection Consortium (PCDC) and Early Detection Research Network – Alliance of Pancreatic Cancer Consortia for Early Detection (EDRN– APaCC) Joint (Virtual) Meeting
DRAFT Agenda
All times are Eastern Standard Time
Time
Session… read more
Co-sponsored by Probiotic and Prebiotic Working Group Speaker Series and the Cancer and Aging Interest Group
Speaker
Claudia C. Cotca, D.D.S., M.P.H.
Founder, Washington Institute for Dentistry & Laser Surgery
Claudia C. Cotca, D.D.S., M.P.H., is an… read more
The NCI Community Oncology Research Program (NCORP) annual meeting for grantees in August 2021 virtually brought together representatives from every NCORP Research Base and Community and Minority Underserved Site to discuss and learn about a range of topics.
A recurring theme was the renewed focus… read more
Agenda
Day #1: Wednesday, December 15 “Charting the Course!”
Moderator: Fred Hochberg, M.D., Consultant, Mass General Hospital
11:00 a.m. – 11:05 a.m.
Welcome
Lynn Sorbara, Ph.D.
Program Director, Cancer Biomarkers Research Group (CBRG) NCI/DCP
11:05 a.m… read more
Physical activity promotion in pediatric populations could be an effective strategy for life course disease prevention, either by primary cancer prevention or by improving outcomes for cancer survivors. However, the journey from etiologic discovery to evidence-based behavioral intervention… read more
If your family member had cancer, would you want to know if you carried a gene mutation that increased your risk of the same cancer? This question is at the heart of three novel research projects underway to determine how best to connect with the family members of women with ovarian cancer so they… read more
We invite you to a virtual presentation with a goal to identify and discuss factors that can influence the reproducibility of results between epidemiological studies and nutritional interventions, identify gaps in knowledge, technical hurdles, and develop new approaches for the development of novel… read more
For older adults undergoing treatment for advanced cancer, results from a clinical trial show that a health measurement tool called a geriatric assessment can be an important part of treatment planning. In the trial, older patients whose care was guided by a geriatric assessment were much less… read more
Fifty years ago this week, the National Cancer Act was signed into law, kick-starting research that has changed how cancer is prevented, detected, diagnosed, treated, and survived, and moving us closer to a time when no one dies of cancer.
President Richard… read more
Welcome to the CP-CTNet Newsletter where we share programmatic and research updates for the Cancer Prevention Clinical Trials Network (CP-CTNet).
Lung cancer, the leading cause of cancer deaths worldwide killing 1.8 million people each year, is often diagnosed at an advanced stage when the chances for a cure are limited.
In the United States, almost 60% of people diagnosed with localized lung and bronchus cancer are likely to survive for 5… read more
A meeting of statistical leads from the seven NCI Community Oncology Research Program (NCORP) Research Bases with statisticians from the Division of Cancer Prevention (DCP) Biometry Research Group took place on July 16, 2021.
Meeting Goals and Content
The meeting had a few key objectives:
To… read more
Key Messages
There are many screening questions that can be addressed through clinical trials.
One size doesn’t fit all: There is a trend for increasingly personalized screening, where cancer screening recommendations are guided by detailed risk assessments, including models.
Promising… read more
Many people being treated for advanced cancer experience serious financial problems related to the cost of their care, even if they have health insurance, according to a new study.
While new cases of most cancer types have dropped over the past decade, cases of the most common type of liver cancer, hepatocellular carcinoma (HCC), are on the rise. Until recently, the main cause of HCC was hepatitis C virus infection. Although hepatitis C infection still causes many… read more
Tumor cells release telltale molecules into blood, urine, and other bodily fluids. But it can be difficult to detect tumor-derived DNA, RNA, and proteins in the earliest stages of disease, when cancers can be easier to treat and cure. Earlier stages shed fewer cancer cells—and fewer tumor markers… read more
Rod Dashwood, Ph.D.
Professor and Center Director
Center for Epigenetics and Disease Prevention
Texas A&M College of Medicine
Bryan, TX
After completing his doctorate degree in the U.K., Dr. Dashwood joined Oregon State University in 1986 as a… read more
This webinar is structured along a translational research perspective (clinical applications to policy) and gives an overview of three NCI-supported projects. Presenters will provide the scientific rationale for exercise interventions and address opportunities and challenges to integrating physical… read more
Philadelphia, March 25, 2022 — The Tomosynthesis Mammographic Imaging Screening Trial (TMIST), is more than halfway to its recruiting goal of 128,905 participants with more than 20% of participants in the United States being Black. Recruitment of women from diverse backgrounds is vital to… read more
Welcome to the CP-CTNet Newsletter where we share programmatic and research updates for the Cancer Prevention Clinical Trials Network (CP-CTNet).
April 8-13, 2022
DCP/PREVENT-funded Project Presentations
Session OPO.IM01.01 - Tumor Immunobiology
5631 - Immunomodulatory activity of sulindac plus erlotinib for colon cancer prevention in familial adenomatous polyposis
Presenter/Authors
Chakrapani Tripathi, Roderick H. Dashwood. Texas A&M… read more
Joyce Ares had just turned 74 and was feeling fine when she agreed to give a blood sample for research. So she was surprised when the screening test came back positive for signs of cancer. After a repeat blood test, a PET scan and a needle biopsy, she was diagnosed with Hodgkin lymphoma.
A… read more
Overall, cancer death rates in the United States have been declining about 2% per year, current SEER data from 2014 through 2018 show. However, these improvements have not been experienced equally by everyone, which is one of the reasons that April is Minority Cancer Awareness Month, when we call… read more
One of the exciting areas of cancer prevention research is the development of noninvasive tests that may have the potential to easily and accurately determine whether and where in the body a person has early-stage cancer. And not just for a single cancer but for many cancers. Over… read more
In the era of personalized medicine, prevention and screening for breast cancer are evolving toward new approaches that assess each woman’s risk and lifestyle factors.
All women do not carry the same risk for the same type of breast cancer. The old one-size-fits-all screening method can miss the… read more
Overview
The Helping to End Addiction Long-term (HEAL) Initiative is a trans-agency effort to address the opioid crisis. One aim of the HEAL Initiative focuses on addressing the crisis by developing better pain management research, techniques, and practices. Opioids are commonly used to manage… read more
Key Messages
Although aspirin use has been studied for decades, there are still many gaps in our understanding its role in cancer prevention.
Risk-benefit analyses should be conducted to ensure that the right patients are receiving aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs)… read more
National Cancer Institute prevention chief discusses steps toward largest U.S. cancer screening trial ever
Unlike many other cancers, the incidence and death rates for uterine cancer are rising.
An example of a nonendometrioid cancer.
Credit: Marina J. Merino, M.D. National Cancer Institute at NIH
Rates of new uterine cancer cases have risen 0.6% per year… read more
Welcome to the CP-CTNet Newsletter where we share programmatic and research updates for the Cancer Prevention Clinical Trials Network (CP-CTNet).
In 2012, Patricia Ganz, M.D., saw a 39-year-old cancer survivor for a consultation who had a long-term history of anxiety during medical visits.
Patricia Ganz, M.D.
The woman had been diagnosed with Hodgkin lymphoma when she was 23 years old. Though her… read more
Research Highlights are a new type of blog for Cancer Prevention Science, where recent publications are highlighted rather than a traditional news story.
This month’s blog post highlights how a cruciferous vegetable extract reduces toxins from tobacco and reports the effects of Polyphenon E in… read more
Recruitment has begun for a clinical study that investigators hope will move “liquid biopsy” technology closer to its still-distant goal: a single blood test for the early detection of cancer. Collectively known as multi-cancer early detection (MCED) assays or sometimes multi-cancer detection… read more
More than half of cancer survivors who were treated with chemotherapy for the four most common types of cancer experienced clinically significant hearing loss and tinnitus after treatment, according to new research.
Christine Miaskowski, RN, Ph.D.
The… read more
A cancer diagnosis can be overwhelming for a developing child and their caregivers due to the physiological, cognitive, and behavioral effects of the cancer itself and the sudden introduction to aggressive clinical management. These powerful cancer therapies can cause pain and suffering for the… read more
Featured Article: CP-CTNet Cross Network Study: Lynch Syndrome. Inherited susceptibility to cancer involves defects in genes that normally function to suppress the formation of tumors. One such syndrome was recognized by Henry Lynch several decades ago based on clinical criteria, but is… read more
This issue of Research Highlights focuses on how cells progress to become breast cancer, and separately, how breast cancer may spread. Understanding these transitional moments can help researchers keep invasive cancer from forming, and help us keep invasive cancer from spreading. One study is about… read more
Cervical cancer can be prevented by human papillomavirus (HPV) vaccination and by screening for and treating precancerous lesions. Yet, millions of women globally remain at high-risk for developing cervical cancer. This is especially true for women living in resource-limited settings in low- and… read more
The National Cancer Institute Division of Cancer Prevention has released three Funding Opportunity Announcements to accept applications to create the Cancer Screening Research Network (CSRN). The CSRN will conduct rigorous, multi-center cancer… read more
This month’s Research Highlights focuses on provider and patient beliefs about mammogram screening frequency, and separately, provider barriers to engaging in shared decision-making with high-risk patients about the use of chemoprevention to reduce breast cancer risk. Both studies discuss the value… read more
The NCI Division of Cancer Prevention will hold pre-application interactive webinars for funding opportunities for the Cancer Screening Research Network (CSRN). The first webinar will provide an overview of the Network, and address all three grants. There will be three subsequent RFA-specific… read more
Cancer treatment-related cardiotoxicity is a leading cause of treatment-associated morbidity and mortality in cancer survivors. The gaps in knowledge related to cardiotoxicity are large, including mechanisms of cardiac injury, clinical risk prediction, screening, prevention, and treatment, as well… read more
TEAG encourages the exchange of information across NCI by coordinating forums to foster interdisciplinary research and collaborations. This forum will highlight two NCI programs designed to support preclinical development of innovative strategies for cancer prevention, through the PREVENT program,… read more
A JNCI monograph on Engaging Older Adults in Cancer Clinical Trials Conducted in the National Cancer Institute Clinical Trials Network is available now. The articles, developed through working groups formed for an NCI workshop held in April… read more
Staff Highlight, DMACC Updates (Data Management and Reporting Unit, CP-CTNET DMACC Public Website and Portal Gateway Update, Clinical Trials Auditing Unit, Administrative and Coordinating Unit), In Memoriam, and Research Funding Opportunities
The National Cancer Institute’s (NCI’s) Board of Scientific Advisors (BSA) recently approved two new concept proposals aimed at expanding potential prevention interventions. One will strengthen research in the nascent field of immunoprevention, and the other will accelerate the development of novel… read more
Speaker
Ashley M. Henneghan, Ph.D., RN, FAAN
School of Nursing
The University of Texas at Austin
As a nurse, Dr. Henneghan's clinical experience has focused on alleviating unwanted symptoms and optimizing function for persons with chronic diseases,… read more
Speaker
Mandi Pratt-Chapman, Ph.D.
Associate Professor of Medicine
GW School of Medicine and Health Sciences
Associate Professor of Prevention and Community Health
GW Milken Institute School of Public Health
Associate Center Director, Community… read more
Clinical Trials
The Effect of Yoga on Nerve Pain Caused by Chemotherapy (Chemotherapy-Induced Peripheral Neuropathy)
The PRISM Intervention for Adolescents and Young Adults Receiving Hematopoietic Cell Transplantation
Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance
Letrozole in Preventing Breast Cancer in Healthy Postmenopausal Women at High Risk for Breast Cancer
Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation
Financial Burden Assessment in Patients With Stage I-III Colon or Rectal Cancer Undergoing Treatment
Improving Patient-Centered Communication in Breast Cancer Through Patient and Provider Interventions
Funding Opportunities and Grants
General Pages
The CSRN will launch a pilot study, called the Vanguard Study, to address the feasibility of using multi-cancer detection (MCD) tests in future randomized controlled trials (RCTs). The Vanguard Study will enroll up to 24,000 people to inform the design of a much larger RCT that will evaluate… read more
On This Page
All Headings will automatically be pulled in to this list.
Do not edit the content on this template.
NCI-Authored Scientific Publications
2024
November 13, 2024: Samimi G, Temkin SM, Weil CJ, Han PKJ, LeeVan E, Rubinstein WS, Swigart TM, Caban S, Dent K, Minasian LM.… read more
On This Page
All Headings will automatically be pulled in to this list.
Do not edit the content on this template.
About Cancer Screening
What are cancer screening tests?
Cancer screening tests are used to check for cancer or… read more
The participating institutions include U01 grants to Research Units (PAR-21-334) and a U24 grant to the Management and Data Coordination Unit (PAR-21-335).
Lessons of Community Engagement Global Partners
Speaker(s): Russell Campbell, M.A., Charles Chasakara, Neetha Morar, M.S., Sheila Bermudez-Agosto
Date: October 11, 2024
Runtime: 01:38:49
Closed captioning is available in English.
A password is required to play this video. Please email ULACNet@… read more
Errors in published Notice RFA-CA-24-025
1. Section III.3 Additional Information on Eligibility. Number of Applications Permitted
The RFA currently has contradictory information that applicant organizations may submit one or more than one application. Only one application per institution is… read more
Errors in published Notice RFA-CA-24-024
1. Letter of Intent (LOI) Due Date
The due date for Letters of Intent is listed as August 23, 2024, which is incorrect. LOI are due 30 days before proposals are due.
The Letter of Intent is due October 1, 2024, and Applications are due by October 31, 2024… read more
Informational Webinar
The pre-application webinars were held on Tuesday, August 27, 2024, from 1:00 pm – 2:00pm ET (RFA-CA-24-024) and from 2:30-3:30pm ET (RFA-CA-24-025). The webinars provided overall information about the NOFOs and address any special requirements for applications submitted to… read more
HPV: Natural History and Its Implications for Screening, Prevention and Treatment
Speaker: Anna-Barbara Moscicki, M.D.
Date: June 10, 2024
Runtime: 01:01:00
Closed captioning is available in English.
A password is required to play this video. Please email ULACNet@nih.gov to obtain the password.
Program Name (Abbreviation)
Resources Available to All Researchers
How to Access
Program Website
Early Detection Research Network (EDRN)
Reference samples for ovary, pancreas, liver, colon, prostate, and other cancer types
For requesting samples, go to: https://… read more
This series is aimed at bringing together interdisciplinary researchers in cancer symptom science to share their expertise and further discussions in the field.
Upcoming Webinar
Diet and Nutrition for Managing Cancer Symptoms
What is the Cancer Screening Research Network (CSRN)?
NCI created the CSRN to develop and conduct multi-center cancer screening trials. These studies will systematically evaluate emerging technologies for cancer screening – such as multi-cancer detection tests (MCDs) – with the goal of… read more
On This Page
All Headings will automatically be pulled in to this list.
Do not edit the content on this template.
Purpose
The National Cancer Institute (NCI) launched the Cancer Screening Research Network (CSRN) in February 2024 to evaluate emerging technologies for cancer screening. The… read more
The National Cancer Institute (NCI) Division of Cancer Prevention (DCP) has created the DCP Early Career Scientist Spotlight Research Seminar Series to highlight nominated early career scientists who are advancing research within the areas… read more
Haiti: GHESKIO Centers Researchers
Speakers: Jean Bernard Marc, M.D., Samuel Pierre, M.D., M.Sc., Genevieve Vanessa Hilaire, M.D., M.Sc.
Date: December 6, 2023
Runtime: 00:58:36
Closed captioning is available in English.
A password is required to play this video. Please email ULACNet@nih.gov to… read more
Experiences of Women Living with HIV Navigating Health Services and Life
Speaker: Gracia Violeta Ross
Date: October 18, 2023
Runtime: 00:58:36
Closed captioning is available in English.
Speakers: Sudhir Srivastava, Ph.D., M.P.H.; Indu Kohaar, Ph.D.
Date: November 9, 2023
Runtime: 00:50:08
PCA Pre-application webinar slides (PPTX, 12.26 MB)
NCI Cervical Cancer ‘Last Mile’ Initiative
Self-collection for HPV testing to Improve Cervical Cancer Prevention (SHIP) Trial
Usability and Acceptability Testing of Devices
Assessment of usability and acceptability of self-collection devices… read more
NCI Cervical Cancer ‘Last Mile’ Initiative (LMI)
Facilitating discussions for regulatory approvals for self-collection
Reviewing evidence on self-collection to inform regulatory pathways
Facilitation of discussions between FDA and HPV assay… read more
NCI Cervical Cancer ‘Last Mile’ Initiative (LMI)
Goal: Overcome barrier of lack of FDA approval for self-collection approaches for HPV testing-based cervical cancer screening
Approach: Engage public and private sector stakeholders to facilitate regulatory… read more
A timely, informative email with the latest DCP research news, funding announcements and deadlines, training opportunities, and more.
Presenter: Vikrant Sahasrabuddhe, M.B.B.S., M.P.H., Dr.P.H.
Deputy Chief, Breast and Gynecologic Cancer Research Group
Program Director, HPV and Cervical Cancer Prevention Clinical Research Program
Division of Cancer Prevention
National Cancer Institute
National Institutes of Health
Tel:… read more
On this page
Eligibility
Network Activities
Budget
Funding Opportunity Announcements (FOAs) for the HIV/Cervical Cancer Prevention ‘CASCADE’ Clinical Trials Network
RFA-CA-21-045: U24 Coordinating Center
RFA-CA-21-046: UG1 Research Bases
RFA-CA-21-047: UG1 Clinical Sites
Eligibility… read more
Discovery and Development of Natural Products for Cancer Interception and Prevention (DDNP-CIP)
ULACNet consists of three Partnership Centers (supported via RFA-CA-18-018) consisting of a US-based Lead Academic Organization and several US and Latin American-based Affiliate Organizations each collaboratively conducting a multidisciplinary Clinical Trials Program.
Partnership Center… read more
Staff Education – Launching a Study
Speakers: Kristin Dahlgren, M.Sc. and Kelly Shrader
Date: April 26, 2023
Runtime: 00:42:16
Closed captioning is available in English.
A password is required to play this video. Please email ULACNet@nih.gov to obtain the password.
2025 Annual Call for Nominations to Highlight Early Career Scientists Conducting Research within the Mission of the NCI Division of Cancer Prevention
Purpose - The purpose for this call for nominations is to highlight early career scientists who are advancing research within the areas supported by… read more
The flow chart shows the steps for discovery and development of natural products (NP) for cancer interception and prevention. The research may use a design along the continuum (such as clinically relevant cancer interception target selection and verification… read more
Current Opportunities
DCP-led Opportunities
Title
Announcement Number
or Website
Expiration Date
or Application Period
Program Official
Highlighting Early Career Scientists in DCP-related Research Areas
View Website
07/31/2025… read more
ULACNet-302: Estudio Oportunidad
Speakers: MPIs: Margaret Madeleine, Ph.D., M.P.H.; Ann Duerr, M.D., Ph.D., M.P.H.; Robinson Cabello, M.D.
Date: February 22, 2023
Runtime: 00:48:15
Closed captioning is available in English and Spanish.
A password is required to play this video. Please email… read more
The requested page could not be found.
Please visit our Homepage or check out one of the following pages:
Cancer prevention and early detection research has been thriving at the National Cancer Institute for more than 45 years. Since 1971, the science of cancer prevention has been infused by the guiding principles of reducing cancer risk and detecting cancer early. Whether the focus of cancer… read more
All grant-funded cancer screening protocols awarded after January 2023 are subject to the new Division of Cancer Prevention (DCP) Screening Protocol Requirements and Slow Accrual Stopping Rules. DCP’s goal is to systematically apply these new requirements to ensure that screening protocols contain… read more
https://prevention.cancer.gov/power/
https://ctrandomization.cancer.gov/
Information for researchers about developing, reporting, and managing NCI-funded cancer prevention clinical trials.
Protocol Information Office (PIO)
The central clearinghouse for clinical trials management within the Division of Cancer Prevention.
Read more about the Protocol Information Office… read more
Go to sites/all/themes/dcp/templates/page--publication-search.tpl.php to edit this page.
PIO Instructions and Tools
Find instructions, forms, and templates for the management of all types of Division of Cancer Prevention clinical trials.
Read more about PIO Instructions and Tools
Clinical Trials Reference Materials
Model clinical agreements, human subject protection and informed… read more
Agreements
For agreement templates, please refer to the respective program’s webpage.
Human Subject Protection/Informed Consent
Tutorials (or Education)
NIH Protecting Human Research Participants
OHRP Human Subject Assurance Training
DHHS/NIH Human Participant Protections… read more
NCORP
Revision or Amendment Submission Checklist For DCP NCORP Studies (DOC, 35.5 KB)
Sample of the NCORP Cancer Care Delivery Research Studies Document Submission Worksheet (DOCX, 719.56 KB… read more
NCI Links
Clinical Trials Management Resource Website
NCI CTCAE v5.0
If You Want to Find Ways to Prevent Cancer…Learn About Prevention Trials
NCI Informed Consent Recommendations and Template
NCI R&D Resources
Certificates of Confidentiality
NIH Links
Required Education in the… read more
Information for investigators relevant to preparation, submission, and tracking of grant applications and peer review.
DCP Resources
Guidance for the Submission of an Awaiting Receipt of Application (ARA)
POSTED: February 27, 2023
Guidance for Cancer Screening Trials
POSTED: February 6, 2023… read more
The National Cancer Institute Division of Cancer Prevention (DCP) is devoted to research on cancer prevention, interception, screening and early detection, and symptom science. To accomplish this, DCP provides funding and administrative support to clinical,… read more
The Breast and Gynecologic Cancer Research Group conducts and fosters the development of research on the prevention and early detection of breast cancer, cervix and human papillomavirus (HPV)-related cancers, endometrial cancers, ovarian cancers, and precursor conditions related to these cancers.… read more
The Lung and Upper Aerodigestive Cancer Research Group conducts and supports research on the prevention and early detection of lung and head and neck cancers, as well as new approaches to clinical prevention studies including cancer immunoprevention.
The Gastrointestinal and Other Cancers Research Group conducts and supports prevention and early detection research on colorectal, esophageal, liver, pancreatic, and hematolymphoid cancers, as well as new approaches to clinical prevention studies including cancer immunoprevention.
Barrett’s… read more
The Early Detection Research Group supports research that seeks to determine the effectiveness, operating characteristics, and clinical impact (harms as well as benefits) of cancer early detection technologies and practices, such as imaging and molecular biomarker approaches.
The group ran two… read more
The Community Oncology and Prevention Trials Research Group supports clinical oncology trials in cancer prevention and control in community settings. The group also supports investigator-initiated research projects in supportive, palliative and end-of-life care, and coordinates clinical oncology… read more
The Chemopreventive Agent Development Research Group promotes and supports research on cancer preventive agent development, from preclinical studies to phase I clinical trials. The group’s projects aim to identify and develop prevention agents with the potential to block, reverse, or delay the… read more
The Cancer Biomarkers Research Group promotes research to identify, develop, and validate biological markers for early cancer detection and cancer risk assessment. Activities include development and validation of promising cancer biomarkers, collaborative databases and informatics systems, and new… read more
The Nutritional Science Research Group (NSRG) promotes and supports studies establishing a comprehensive understanding of the precise role of diet and food components in modifying cancer risk and tumor cell behavior. This focus includes approaches to characterize molecular targets and variability… read more
The Prostate and Urologic Cancer Research Group conducts and supports research on prostate and bladder cancers, and new approaches to clinical prevention studies including cancer immunoprevention. The group develops, implements and monitors research efforts in chemoprevention, nutrition, genetic,… read more
To log out, please close your browser.
By Stuart G. Baker, 2017
Introduction
A risk prediction marker is a baseline variable for predicting an event that is used to make treatment decisions for persons at high risk for the event. This program compares two risk prediction models: Model 1, which is the baseline model and Model 2, which… read more
By Stuart G. Baker
The composite linear models software is a matrix approach to compute maximum likelihood estimates and asymptotic standard errors for models for incomplete multinomial data. It implements the method described in Baker SG. Composite linear models for incomplete multinomial data.… read more
Stuart G. Baker, 2014
Introduction
This program fits biologically relevant response curves in comparative analysis of the two gene expression experiments involving same genes but under different scenarios and at least 12 responses. The program outputs gene pairs with biologically relevant… read more
By Stuart G. Baker, 2015
Introduction
A predictive marker is a baseline variable in a randomized trial that is used to determine subgroups in which the effect of treatment is greater than average. This software uses a modified adaptive signature design to evaluate a randomized trial with a… read more
By Stuart G. Baker, 2017
Introduction
This software fits a zero-intercept random effects linear model to data on surrogate and true endpoints in previous trials.
Requirement: Mathematica Version 11 or later.
To run the program
copy
all files into some folder called "FOLDER… read more
By Stuart G. Baker
The program requires Mathematica 7.01.0
The key function is Classify [datalist,options] where
datalist={data, genename, dataname}
data ={matrix for class 0, matrix for class 1}, matrix is gene expression by specimen genename a list of names of genes,
dataname ={name of data… read more
This lecture series features extraordinary contributors in the field of cancer and nutrition research. Speakers highlight the important role that nutrition plays in modifying cancer development. Past lectures can be viewed on the NIH VideoCast website.
Past Lectures
Lifestyle and Breast Cancer… read more
Attendee Testimonial
Plenty of Food for Thought Served Up at the John Milner Nutrition and Cancer Prevention Research Practicum by Julia Tobacyk
View the Testimonial (PDF, 789.65 KB)
Dates and Locations
The John Milner Practicum for 2023 … read more
By Stuart G. Baker, 2015
Introduction
A predictive marker is a baseline variable in a randomized trial that is used to determine subgroups in which the effect of treatment is greater than average. The software splits the data into training and test samples. The model fits a benefit function to… read more
By Stuart G. Baker, 2015
Introduction
The latent class twin method assumes two types of latent classes: an environmental susceptibility (ES) latent class and a genetic susceptibility (GS) latent class. The GS latent class represents a genetic contribution (arising from an additive, autosomal… read more
The program supports research in three areas: prevention or treatment of acute or chronic symptoms and morbidities related to cancer, its treatment and caregiving (symptom management research); effects on quality of life from cancer, its treatment and caregiving (quality of life research); and end-… read more
Cancer treatment-related cardiotoxicity is damage to the heart and/or cardiovascular system (including heart valves and vessels) that can occur during or after cancer treatment (see more in this blog post). Chemotherapy and radiation therapy, as well as newer forms of cancer treatment like immune… read more
Supported Approaches
PREVENT supports these approaches to prevention:
Immunoprevention (e.g., vaccines for cancers associated or not associated with infectious agents, immunomodulatory agents)
Chemoprevention (e.g., novel mechanisms, novel agents, anti-inflammatory approaches, drug repurposing… read more
General Instructions
Please apply using the PREVENT Application System.
Next application deadlines are June 2, 2025, and November 3, 2025.
Required Documents
PREVENT Concept Application (DOCX, 35.18 KB)
For Resubmissions: The NCI will accept only… read more
Infographic Highlight
PREVENT Cancer Preclinical Drug Development Program (PREVENT) supports the best ideas in cancer prevention using NCI contract resources
View the infographic
PREVENT is a peer-reviewed program designed to support development of the… read more
The Interactive Diet and Activity Tracking in AARP (IDATA) Study is a methodologic study of device-based, internet-based, and conventional self-report instruments for assessing physical activity and diet in epidemiologic research. Scientists still have… read more
On This Page
All Headings will automatically be pulled in to this list.
Do not edit the content on this template.
For more information on available resources, please contact: NCIDCPPREVENT@mail.nih.gov.
Efficacy
Expertise is available for conducting preclinical efficacy and biomarker… read more
Governance Structure
Because of the importance of an integrated approach to preventative drug development, the PREVENT program is administered through a unified governance structure for coordinating and integrating available resources. With the goal of reaching go or no-go decisions as efficiently… read more
2024-2029
Preclinical Efficacy & Intermediate Endpoint Biomarkers
Organization
Principal Investigator
Board of Regents of the University of Oklahoma
Health Sciences Center
Chinthalapally V. Rao, Ph.D.
George Lynn Cross Professor
Phone: 405-271-3224… read more
Principal Investigator: Michael Hollingsworth, Ph.D.
Institution: University of Nebraska, Omaha, NE
Member Information
Publications
View publications by Hollingsworth
The Hollingsworth Tumor Glycomics Laboratory focuses on pancreatic cancer and other diseases of the pancreas, primarily… read more
By Stuart G. Baker, 2017
Introduction
This software computes meta-analysis and extrapolation estimates for an instrumental variable meta-analysis of randomized trial or before-and-after studies (the latter also known as the paired availability design). The software also checks on the… read more
Armstrong BG. Effect of measurement error on epidemiological studies of environmental and occupational exposures. Occupational and Environmental Medicine 1998; 55:651-656.
Bhadra A, Wei R, Keogh R, Kipnis V, Midthune D, Buckman DW, Carroll RJ. Measurement error models with zero inflation and hard… read more
3.1. NCI software for different applications
NCI Method Software Applications and Zip Filenames July 2018
Download the file (PDF, 434.62 KB)
The NCI software comprises a suite of SAS macros that may… read more
2.1. Basic concepts of measurement error
In epidemiology, errors in measurement of dietary intakes are widespread, and statistical methods for dealing with them have been developed in some depth.
The errors in assessing dietary intake depend upon the dietary instrument used. Commonly used… read more
1.1. Basic concepts of measurement error
In epidemiology, the variables of interest are often measured with error. This is true not only for variables that are self-reported, such as lifestyle behavior, but also for variables derived from laboratory tests, such as serum cholesterol.
When one… read more
This primer is intended for those who wish to know more about the statistical issues underlying measurement error, its impact on research results, and statistical methods of adjusting for its unwanted effects, especially as applied to nutrition research. The material is arranged in three sections.… read more
Programs and related files for examples on this page
Download files (ZIP, 14.53 MB)
Macros
MULTIVAR_MCMC
BOXCOX_SURVEY
STD_COV_BOXCOX24HR_CONDAY_MINAMT
MULTIVAR_DISTRIB
Procedure
First, choose a Box-… read more
Programs and related files for examples on this page
Download files (ZIP, 3.39 MB)
Macros
NLMIXED UNIVARIATE
NLMIXED BIVARIATE
PREDICT_INTAKE_DENSITY
Procedure
First, call the NLMIXED_UNIVARIATE macro… read more
Macros
MULTIVAR_MCMC
BOXCOX_SURVEY
STD_COV_BOXCOX24HR_CONDAY_MINAMT
MULTIVAR_DISTRIB
Procedure
First, choose a Box-Cox transformation parameter for the nonzero amounts of each dietary variable. The BOXCOX_SURVEY macro or PROC TRANSREG in SAS can be used to perform this task.
Because… read more
Macros
NLMIXED UNIVARIATE
NLMIXED BIVARIATE
PREDICT_INTAKE_DENSITY
Procedure
First, call the NLMIXED_UNIVARIATE macro twice (once for each variable) to get starting estimates for subsequent NLMIXED_BIVARIATE calls.
Because replication methods (bootstrap or BRR) are used to estimate… read more
Programs and related files for examples on this page
Download files (ZIP, 219.31 KB)
Macros
MIXTRAN
DISTRIB
BOXCOX_SURVEY
INDIVINT
Procedure
Because replication methods (bootstrap or BRR) are used to… read more
Programs and related files for examples on this page
Download files (ZIP, 14.52 MB)
Macros
MULTIVAR_MCMC
BOXCOX_SURVEY
STD_COV_BOXCOX24HR_CONDAY_MINAMT
MULTIVAR_DISTRIB
Procedure
First, choose a Box-… read more
Programs and related files for examples on this page
Download files (ZIP, 14.52 MB)
Macros
NLMIXED UNIVARIATE
NLMIXED BIVARIATE
PREDICT_INTAKE_DENSITY
Procedure
First, call the NLMIXED_UNIVARIATE macro… read more
Macros
MULTIVAR_MCMC
BOXCOX_SURVEY
STD_COV_BOXCOX24HR_CONDAY_MINAMT
MULTIVAR_DISTRIB
Procedure
First, choose a Box-Cox transformation parameter for the nonzero amounts of each dietary variable. The BOXCOX_SURVEY macro or PROC TRANSREG in SAS can be used to perform this task.
Because… read more
Programs and related files for examples on this page
Download files (ZIP, 14.5 MB)
Macros
MIXTRAN
INDIVINT
Procedure
Because replication methods (bootstrap or BRR) are used to estimate standard errors… read more
Macros
NLMIXED UNIVARIATE
NLMIXED BIVARIATE
PREDICT_INTAKE_DENSITY
Procedure
First, call the NLMIXED_UNIVARIATE macro twice (once for each variable) to get starting estimates for subsequent NLMIXED_BIVARIATE calls
Because replication methods (bootstrap or BRR) are used to estimate standard… read more
Programs and related files for examples on this page
Download files (ZIP, 14.55 MB)
Macros
MULTIVAR_MCMC
BOXCOX_SURVEY
STD_COV_BOXCOX24HR_CONDAY_MINAMT
MULTIVAR_DISTRIB
Procedure
First, choose a Box-… read more
Programs and related files for examples on this page
Download files (ZIP, 14.55 MB)
Macros
MULTIVAR_MCMC
BOXCOX_SURVEY
STD_COV_BOXCOX24HR_CONDAY_MINAMT
MULTIVAR_DISTRIB
Procedure
First, choose a Box-… read more
Programs and related files for examples on this page
Download files (ZIP, 12.65 MB)
Macros
MULTIVAR_MCMC
BOXCOX_SURVEY
STD_COV_BOXCOX24HR_CONDAY_MINAMT
MULTIVAR_DISTRIB
PERCENTILES_SURVEY
BRR_PVALUE_CI… read more
Programs and related files for examples on this page
Download files (ZIP, 11.8 MB)
Macros
NLMIXED UNIVARIATE
BOXCOX_SURVEY
NLMIXED BIVARIATE
DISTRIB_BIVARIATE
PERCENTILES_SURVEY
BRR_PVALUE_CI… read more
Programs and related files for examples on this page
Download files (ZIP, 12.48 MB)
Macros
MIXTRAN
DISTRIB
BRR_PVALUE_CI
Procedure
Because replication methods (bootstrap or BRR) are used to estimate… read more
Macros
MULTIVAR_MCMC
BOXCOX_SURVEY
STD_COV_BOXCOX24HR_CONDAY_MINAMT
MULTIVAR_DISTRIB
PERCENTILES_SURVEY
BRR_PVALUE_CI
Procedure
First, choose a Box-Cox transformation parameter for the nonzero amounts of the dietary variable. The BOXCOX_SURVEY macro or PROC TRANSREG in SAS can be used to… read more
Macros
NLMIXED UNIVARIATE
NLMIXED BIVARIATE
DISTRIB_BIVARIATE
PERCENTILES_SURVEY
BRR_PVALUE_CI
Procedure
First, call the NLMIXED_UNIVARIATE macro twice (once for each variable) to get starting estimates for subsequent NLMIXED_BIVARIATE calls.
Because replication methods (bootstrap or BRR… read more
The Biometry Research Group supports cancer prevention research through a variety of activities, including statistical reviews, consultations, and development of statistical models and methodologies. The group identifies problems in real-world scientific applications and creates requirements… read more
By Stuart G. Baker, 2019
Introduction
This software supports the mathematical investigation into estimating the fraction of cancers detected on screening that are overdiagnosed.
References
Baker SG and Prorok PC. Overdiagnosis in cancer screening: Improved excess incidence estimation.… read more
CP-CTNet Organizational Rosters
CP-CTNet Roster Management System
Guidelines for Modifications to a Lead Academic Organizational Roster (DOCX, 26.15 KB)
Protocol Development
CP-CTNet… read more
Protocol Development
Protocol Template (DOCX, 113.33 KB)
Informed Consent Template (DOCX, 65.53 KB)
Ancillary Protocol Template (DOCX, 60.81… read more
The following information specifies the general technology transfer considerations for the PREVENT applicants related to the intellectual property (IP) and licensing mechanisms applicable to the studies in the PREVENT Program.
PREVENT Collaboration Agreement
Applicants whose concept proposals are… read more
Oral Histories
Past Reports
20th Anniversary of the National Cancer Act
Ford, Leslie
Interview date: December 17, 2008
Greenwald, Peter
Interview date: October 17, 2008
Interview date: December 4, 2008
Interview date: December 12, 2008
Kaluzny, Arnold G.… read more
POSTED: March 18, 2024
The Research Program Project Grant (P01) supports investigator-initiated multi-project research programs with a major objective or theme relevant to cancer research. It involves large, multidisciplinary groups and shared resources. Each project is related to the common theme… read more
Required for Unsolicited Large Grant Applications
(≥$500K or more direct costs, in any single year of the grant)
Requirements
For grant applications (e.g., R01, U01, or P01) with direct costs of $500,000 or more in any one year (regardless of the average per year)*, the National Cancer Institute… read more
Jump to: Colon | Endometrium/ Uterus | Esophagus | Head and Neck | Liver | Lung | Mammary Gland | Mesothelioma | Other, Solid Tumors | Ovary | Pancreas | Prostate | Urinary Bladder
Organ Site
High Risk Cohort
Species (Strain)
Method of Tumor Induction
Endpoint(s)… read more
Funding Opportunity Announcements (FOAs)
Subscribe to ULACNet Update.
Since 2021, the NCI Division of Cancer Prevention (DCP) has supported an initiative for the US-Latin American-Caribbean HIV/HPV Cancer Prevention Clinical Trials Network (ULACNet) focused on community engagement and site education activities. With the launch of the HIV/Cervical Cancer Prevention ‘… read more
The toxicity and tolerability of cancer therapies are important for many reasons: patients who experience bad side effects may not be able to finish their full course of treatment, reducing their chance of successful treatment. Often, side effects of cancer… read more
Through these Funding Opportunity Announcements (FOAs), the National Cancer Institute (NCI) intends to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors, screening, early detection,… read more
The U01 Tolerability Consortium is organized into four grant teams, with a steering committee comprised of members of each team and group of NCI and FDA Stakeholders. More about each of these groups can be found in the sections below.
Steering… read more
As the individual research teams working on their projects and joined U01 meetings, several ideas became cross-collaborations and led to the formation of working groups. The purpose of these are to delve into a specific idea and support the consortium and research community, at-large.
GP5… read more
Presented as part of the ISOQOL (International Society for Quality of Life Research) 27th Annual Conference (October 2020). Symposium: “Integrating Adverse Event Data and Patient-Reported Outcomes to Better Understand Cancer Treatment Tolerability: The US National Cancer Institute-Funded… read more
Selected Tolerability Consortium Publications
2023
Culakova E, Mohile SG, Peppone L, Ramsdale E, Mohamed M, Xu H, Wells M, Tylock R, Java J, Loh KP, Magnuson A, Jamieson L, Vogel V, Duberstein PR, Chapman BP, Dale W, Flannery MA. Effects of a Geriatric Assessment Intervention on Patient-… read more
The following resources and tools have been compiled by consortium members as part of the standardization working group. These resources and tools can be used as guidance for researchers and other stakeholders interested in summarizing and visualizing patient tolerability data:
Selected Scoring… read more
Pre-Application Webinar for RFA-CA-22-031 and RFA-CA-22-032
The National Cancer Institute (NCI) held a public pre-application webinar on September 26, 2022.
Link to Notice about Webinar: https://grants.nih.gov/grants/guide/notice-files/NOT-CA-22-121.html.
On this page
Meeting Recordings and… read more
Nine-Valent HPV Vaccinne to Prevent Persistent Oral HPV Infection in Men Living with HIV
Speakers: Kim Isaacs-Soriano, M.P.H.
Moffitt Cancer Center;
Date: June 6, 2022
Runtime: 01:00:35
A password is required to play this video. Please email ULACNet@nih.gov to obtain the… read more
Recruitment Strategies
Speaker: Vanessa Gómez Vargas
University of Puerto Rico Comprehensive Cancer Center
Date: March 25, 2022
Runtime: 01:01:35
A password is required to play this video. Please email ULACNet@nih.gov to obtain the password.
A video recording of this session is unavailable. Please contact ULACNet@nih.gov for more information.
On This Page
All Headings will automatically be pulled in to this list.
Do not edit the content on this template.
Pre-Application Webinar for RFA-CA-23-018 and RFA-CA-23-019
The National Cancer Institute (NCI) held a public pre-application webinar on December 22, 2022 1:00 PM-2:00 PM EDT;… read more
A research blog from the NCI Division of Cancer Prevention
Subscribe
Cancer prevention videos and webinars related to DCP programs are listed here.
Tap on the desired thumbnail below to view its larger version where you may share the infographic via Twitter and Facebook or download the image by clicking on the appropriate icon:
The Division of Cancer Prevention honors the champions and changemakers of cancer prevention, early detection and symptom science.
The NCI Division of Cancer Prevention funds new research in cancer prevention, detection, screening, interception, and symptom management. We also fund programs to train people for careers in research. Explore current open funding opportunities here and… read more
The following graphic notice means that you are leaving this Web site:
This external link provides additional information that is consistent with the intended purpose of this site.
The National Cancer Institute (NCI) cannot attest to the accuracy of a non-federal site.
Linking to a non-… read more
Research Area
The Pre-cancer Atlas (PCA) Research Centers are part of the Human Tumor Atlas Network (HTAN). HTAN, an NCI-collaborative program, is constructing multi-dimensional atlases of the cellular, morphological, molecular, and spatial features of human cancers and… read more
The Cancer Immunoprevention Network (CIP-Net) supports the development of approaches that leverage the immune system to prevent cancers. Research in CIP-Net is advancing a deeper understanding of basic mechanisms of immunoprevention and promoting the… read more
The Discovery and Development of Natural Products for Cancer Interception and Prevention Program (DDNP-CIP) supports the discovery and development of new natural products that are safe, non-toxic, and useful for cancer interception and prevention. Given the… read more
The NCI Cancer Tolerability Consortium is a consortium of multidisciplinary teams that is developing new methods for analyzing patient-reported outcomes in the setting of cancer clinical trials. These methods will better define patient tolerability to cancer… read more
The US-Latin American-Caribbean HIV/HPV-Cancer Prevention Clinical Trials Network (ULACNet) focuses on developing evidence to improve and optimize approaches for prevention of human papillomavirus (HPV)-related cancers in people living with human immunodeficiency virus (HIV) infection.
Scientific… read more
The Translational Liver Cancer (TLC) Consortium was established to advance translational research focused on early detection of liver cancer. The consortium goals are to conduct studies to improve the surveillance of liver cancer in high-risk populations,… read more
Visit the TBEL Website
The Translational and Basic Science research in Early Lesions (TBEL) program is a collaborative research network that aims (1) to further understand the biological and pathophysiological mechanisms driving or restraining… read more
The Supportive Care and Symptom Management program supports studies on the prevention or treatment of acute and chronic symptoms and morbidities related to cancer and its treatment. This includes the impact on the quality of life of patients and their… read more
The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial was a large randomized controlled trial designed and sponsored by the National Cancer Institute (NCI). The goal was to determine the effects of screening on cancer-related mortality and secondary endpoints in men and women… read more
The Pancreatic Cancer Detection Consortium (PCDC) develops and tests new molecular and imaging biomarkers to detect early stage pancreatic ductal adenocarcinoma (PDAC) and its precursor lesions. These biomarkers would be used to identify individuals who are… read more
The PREVENT program is a peer-reviewed agent development program designed to support preclinical development of innovative interventions and biomarkers for cancer prevention and interception towards clinical trials. All interested researchers with novel… read more
Visit the NCORP Website
The NCI Community Oncology Research Program (NCORP) is a national network of cancer care investigators, providers, academia, and other organizations that care for diverse populations in health systems.
The DCP Community… read more
Cervical cancer, caused by human papillomavirus (HPV), is highly preventable by HPV vaccination and by early detection and treatment of cervical precancerous changes. Yet, over half of all cervical cancer cases diagnosed in the United States occur in… read more
Lung cancer – the leading cause of cancer-related deaths in the United States – kills more people than cancers of the breast, prostate, and colon combined. By the time lung cancer is diagnosed, the disease has often already spread outside the lung.… read more
Visit the CASCADE Website
NCI’s HIV/Cervical Cancer Prevention ‘CASCADE’ Clinical Trials Network is a cooperative agreement-funded program focused on pragmatic clinical trials to optimize the cervical cancer screening, management, and precancer… read more
Visit the EDRN Website
The Early Detection Research Network (EDRN) is a collaborative program that maintains comprehensive infrastructure and resources critical to the discovery, development and validation of biomarkers for cancer risk and early… read more
The Consortium for Imaging and Biomarkers (CIB) seeks to improve cancer screening, early detection of aggressive cancer, assessment of cancer risk, and cancer diagnosis by integrating imaging strategies with biomarkers into complementary approaches.
On… read more
The Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT) is a collaborative research network with the goal of discovering targeted agents to prevent or intercept the development of cancer in higher-risk populations.
On This Page
All Headings will automatically be pulled in… read more
Visit the CPFP Website
The Cancer Prevention Fellowship Program (CPFP) is renowned for providing a strong foundation for scientists and clinicians to train in the field of cancer prevention and control.
On This PageAbout CPFPApplication… read more
The Cancer Prevention Clinical Trials Network (CP-CTNet) performs early phase clinical trials to assess the safety, tolerability, and cancer preventive potential of agents and interventions. By conducting prevention studies on people at increased risk due to… read more
Featured Infographic
Liquid Biopsy: A new, noninvasive technique that can detect disease biomarkers in blood, urine, and sputum.
View the infographic
In the era of personalized medicine, having minimally invasive methods to determine and follow the… read more
Landing Pages
Carefully collected and controlled high-quality human biospecimens, annotated with clinical data and properly consented for investigational use, are available through the Division of Cancer Prevention Biorepositories listed in the charts below.
Biorepositories Managed by the Division of Cancer… read more
The National Surgical Adjuvant Breast and Bowel Project (NSABP) has a serum and lymphocyte bank with specimens on more than 90% of the 33,000 women in the Breast Cancer Prevention Trial (BCPT) and Study of Tamoxifen and Raloxifene (STAR). They also have tumor blocks on the majority of the breast… read more
The PCPT biorepository and extended data was used to further explore the initial suggestion that some men taking finasteride were at risk of developing high-grade prostate cancers, and to look at the value of prostate-specific antigen (PSA) for early detection. Researchers showed that:… read more
As the largest prostate cancer prevention trial ever undertaken, the Selenium and Vitamin E Cancer Prevention Trial (SELECT) has assembled a substantial biorepository of specimens. To help make SELECT resources available to a wider research community, NCI and the Southwest Oncology Group are… read more
The Cancer Data Access System (CDAS) is a submission and tracking system for researchers to request data from various research studies. For some studies, images and biospecimens are also available to request. The following studies are currently available on CDAS:
National Lung Screening Trial (… read more
The Etiology and Early Marker Studies (EEMS) is a component of the PLCO Trial. By collecting biologic materials and risk factor information from trial participants before the diagnosis of disease, PLCO EEMS adds substantial value to the trial, providing a resource for cancer research, focused, in… read more
NCI supports the continued follow-up of PLCO participants to strengthen the PLCO as a valuable resource for epidemiologic research, as well as to provide long-term data on the trial’s primary endpoints.
To achieve this, we are:
Carrying out periodic linkages with state cancer registries and the… read more
The Division of Cancer Prevention (DCP) is the division of the National Cancer Institute (NCI) devoted to cancer prevention research. DCP provides funding and administrative support to clinical and laboratory researchers, community and multidisciplinary teams, and collaborative scientific networks… read more
Scientific resources for research on cancer prevention, early detection and screening are made available through DCP support.
Ten Research Groups promote and support the Division’s portfolio of grants and contracts to external investigators, and conduct original research. Investigators supported by the Division are generating new information about molecular processes that are vulnerable to interventions; developing… read more
The Division of Cancer Prevention supports major scientific collaborations, research networks, investigator-initiated grants, postdoctoral training, and specialized resources across the United States.
DCP funds and provides administrative support to clinical and laboratory researchers, community and multidisciplinary teams, and collaborative scientific networks.
Information about actively enrolling, ongoing, and completed clinical trials of cancer prevention, early detection, and supportive care, including phase I, II, and III agent and action trials and clinical trials management.